SS-31 Evidence Guide
Elamipretide is now FDA-approved, but only for improving muscle strength in Barth syndrome patients who weigh at least 30 kg, under accelerated approval. The randomized pivotal trial missed its primary endpoints, and evidence does not support extending the result to longevity, heart failure, or general mitochondrial enhancement.
Our Take
Elamipretide is now FDA-approved, but only for improving muscle strength in Barth syndrome patients who weigh at least 30 kg, under accelerated approval. The randomized pivotal trial missed its primary endpoints, and evidence does not support extending the result to longevity, heart failure, or general mitochondrial enhancement.
- Evidence context
- Approved Barth-syndrome use and research on cardiolipin-targeted mitochondrial biology
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Regulatory label reference: Forzinity label: 40 mg subcutaneous once daily for the approved Barth-syndrome population
Benefits and Evidence
- Mitochondrial Function: Level B, includes human evidence - Consistent improvement in mitochondrial function across preclinical and clinical studies. Restores impaired mitochondrial energetics in aging and disease models.
- Barth Syndrome Muscle Strength: Level B, includes human evidence - FDA granted accelerated approval based on knee-extensor muscle-strength findings and open-label follow-up in 12 patients. The randomized trial did not show superiority on its primary six-minute walk or fatigue endpoints, so confirmatory evidence remains necessary.
- Heart Failure: Level B, includes human evidence - PROGRESS-HF did not improve left-ventricular end-systolic volume or six-minute walk distance versus placebo after four weeks. Heart-failure efficacy is not established and is outside the approved indication.
- Exercise Capacity: Level B, includes human evidence - TAZPOWER did not meet its randomized primary six-minute walk or fatigue endpoints. Longer open-label follow-up suggested improvement, but uncontrolled extension results are less reliable than the randomized comparison.
- Kidney Protection: Level C, includes human evidence - Preliminary evidence of renoprotective effects, particularly in ischemia-reperfusion injury. Clinical trials ongoing for acute kidney injury prevention.
Side Effects and Warnings
- Injection-site reactions are the most common adverse reactions
- Headache
- Mild gastrointestinal symptoms
- Hypersensitivity reactions and eosinophilia have been reported
- Accelerated approval is limited to Barth syndrome in patients weighing at least 30 kg
- Confirmatory clinical benefit is still required
- The randomized pivotal study did not meet its primary walk-distance or fatigue endpoints
- Monitor for hypersensitivity and clinically significant injection-site reactions under the approved label
Research Dosage References
- <strong>Subcutaneous injection (Forzinity label)</strong> - 40 mg - Once daily - FDA-labeled dosage for patients with Barth syndrome who weigh at least 30 kg. This is indication-specific prescribing information, not a general mitochondrial protocol.
- <strong>Intravenous</strong> - 0.05 mg/kg/hr - Continuous infusion - Used in acute settings (cardiac surgery, reperfusion injury). Duration varies by protocol.
Mechanism of Action
SS-31 targets mitochondrial function: 1. Cardiolipin binding: Selectively binds to cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure. 2. Electron transport optimization: Improves electron flow through the respiratory chain, reducing electron leak and ROS production. 3. ATP production enhancement: Increases mitochondrial ATP output by optimizing oxidative phosphorylation. 4. ROS reduction: Decreases mitochondrial reactive oxygen species at their source rather than scavenging after production. 5. Mitochondrial dynamics: Promotes healthy mitochondrial fusion/fission balance and prevents pathological fragmentation.
Legal Status
FDA granted Forzinity (elamipretide) accelerated approval on September 19, 2025 to improve muscle strength in adults and pediatric patients with Barth syndrome who weigh at least 30 kg. It remains investigational for heart failure, aging, kidney injury, and other mitochondrial conditions. Continued approval for Barth syndrome may depend on a confirmatory trial.
Primary Sources
- Elamipretide in Heart Failure with Preserved Ejection Fraction: The PROGRESS-HF Trial. J Card Fail, 2020.
- A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate elamipretide in Barth syndrome: TAZPOWER. Genet Med, 2021.
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome. Genet Med Open, 2024.
- Elamipretide: First Approval. Drugs, 2026.
- FDA grants accelerated approval for the first treatment for Barth syndrome. FDA Drug Approval, 2025.
- Drug Trials Snapshot: Forzinity. FDA Drug Trials Snapshots, 2025.
Quick Answers
Where is the strongest evidence for SS-31?
Elamipretide is now FDA-approved, but only for improving muscle strength in Barth syndrome patients who weigh at least 30 kg, under accelerated approval. The randomized pivotal trial missed its primary endpoints, and evidence does not support extending the result to longevity, heart failure, or general mitochondrial enhancement. Evidence context: Approved Barth-syndrome use and research on cardiolipin-targeted mitochondrial biology.
What are the main side effects of SS-31?
SS-31 side effects and warning signals include Injection-site reactions are the most common adverse reactions, Headache, Mild gastrointestinal symptoms, Hypersensitivity reactions and eosinophilia have been reported, and Accelerated approval is limited to Barth syndrome in patients weighing at least 30 kg.
What evidence level is SS-31?
SS-31 is rated Level B; the listed research status is FDA Approved.